Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Fmr LLC

Fmr LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 36.7% in the second quarter, Holdings Channel reports. The fund owned 3,509,057 shares of the biopharmaceutical company’s stock after buying an additional 942,147 shares during the period. Fmr LLC’s holdings in Gilead Sciences were worth $241,634,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Albion Financial Group UT acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $27,000. Sawyer & Company Inc acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $28,000. Meridian Wealth Partners LLC acquired a new stake in Gilead Sciences in the 1st quarter valued at about $32,000. Elmwood Wealth Management Inc. acquired a new stake in Gilead Sciences in the 1st quarter valued at about $35,000. Finally, Samalin Investment Counsel LLC acquired a new stake in Gilead Sciences in the 2nd quarter valued at about $58,000. Institutional investors own 78.04% of the company’s stock.

In other Gilead Sciences news, CAO Diane E. Wilfong sold 13,610 shares of the firm’s stock in a transaction that occurred on Tuesday, August 17th. The shares were sold at an average price of $72.50, for a total value of $986,725.00. Following the completion of the transaction, the chief accounting officer now owns 30,179 shares of the company’s stock, valued at approximately $2,187,977.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.12% of the company’s stock.

Several analysts have recently weighed in on the stock. Royal Bank of Canada reissued a “buy” rating and issued a C$84.00 price target on shares of Gilead Sciences in a research note on Monday, August 23rd. Morgan Stanley increased their price target on shares of Gilead Sciences from $83.00 to $84.00 and gave the company an “overweight” rating in a research note on Tuesday. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating and set a $72.00 price target for the company in a research note on Tuesday, August 10th. SVB Leerink increased their price target on shares of Gilead Sciences from $74.00 to $77.00 and gave the company an “outperform” rating in a research note on Friday, July 30th. Finally, Oppenheimer assumed coverage on shares of Gilead Sciences in a research note on Monday, June 28th. They issued a “buy” rating and a $100.00 price target for the company. Eight analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $105.72.

Shares of GILD stock opened at $67.63 on Thursday. The company has a quick ratio of 1.19, a current ratio of 1.36 and a debt-to-equity ratio of 1.42. Gilead Sciences, Inc. has a 52 week low of $56.56 and a 52 week high of $73.34. The stock has a market capitalization of $84.80 billion, a PE ratio of 16.50, a P/E/G ratio of 0.63 and a beta of 0.39. The firm has a 50 day moving average of $70.59 and a two-hundred day moving average of $68.42.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, July 29th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.76 by $0.11. Gilead Sciences had a net margin of 19.38% and a return on equity of 55.94%. The company had revenue of $6.22 billion during the quarter, compared to analysts’ expectations of $6.15 billion. During the same quarter last year, the company posted $1.11 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.15 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 29th. Shareholders of record on Wednesday, September 15th were given a $0.71 dividend. The ex-dividend date of this dividend was Tuesday, September 14th. This represents a $2.84 annualized dividend and a yield of 4.20%. Gilead Sciences’s dividend payout ratio is presently 40.06%.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Featured Story: The limitations of an equal weight rating

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.